^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | HB0030 (TIGIT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase Ia trial to evaluate the safety and efficacy of HB0030, an anti-TIGIT antibody, in patients with advanced solid tumors: Preliminary results.
Published date:
05/25/2023
Excerpt:
The ORR and DCR were 6.3% (1/16) and 62.5% (10/16), respectively. The best response was a PR with 47% tumor regression pt who was diagnosed non-small cell lung cancer (NSCLC) accompanied with TP53 gene mutation...HB0030 showed very well safety in the stage of dose escalation from 0.1 to 20 mg/kg, and potential promising anti-tumor activity above 3mg/kg dose in advanced solid tumors pts, especially in NSCLC.
DOI:
10.1200/JCO.2023.41.16_suppl.e14673
Trial ID:
